Marinus Pharmaceuticals (MRNS)
(Delayed Data from NSDQ)
$1.60 USD
+0.09 (5.96%)
Updated Sep 19, 2024 04:00 PM ET
3-Hold of 5 3
F Value C Growth C Momentum F VGM
Cash flow Statements
Fiscal Year End for Marinus Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -141.41 | -19.82 | -98.78 | -67.48 | -54.12 |
Depreciation/Amortization & Depletion | 0.21 | 1.03 | 0.90 | 0.34 | 0.27 |
Net Change from Assets/Liabilities | 2.17 | -6.09 | 28.70 | -2.04 | -0.59 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 21.03 | -88.01 | 13.70 | 8.27 | 5.81 |
Net Cash From Operating Activities | -118.00 | -112.89 | -55.48 | -60.91 | -48.63 |
Property & Equipment | -0.11 | -1.60 | -1.10 | 0.00 | -0.39 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 107.38 | 0.00 | 0.00 | 0.00 |
Investments | -28.50 | 0.00 | 1.47 | -0.74 | 4.27 |
Other Investing Activities | 0.00 | 0.00 | -1.79 | 0.00 | 0.00 |
Net Cash from Investing Activities | -28.61 | 105.77 | -1.42 | -0.74 | 3.88 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 26.63 | 66.27 | 1.20 | 109.22 | 67.97 |
Issuance (Repayment) of Debt | 0.00 | 29.88 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 28.59 | 40.26 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | -0.15 | 0.00 | 0.00 |
Net Cash from Financing Activities | 26.63 | 124.74 | 41.31 | 109.22 | 67.97 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -119.98 | 117.62 | -15.58 | 47.57 | 23.22 |
Cash at Beginning of Period | 240.55 | 122.93 | 138.51 | 90.94 | 67.73 |
Cash at End of Period | 120.57 | 240.55 | 122.93 | 138.51 | 90.94 |
Diluted Net EPS | -2.63 | -0.51 | -2.69 | -2.80 | -3.96 |
Fiscal Year End for Marinus Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -74.50 | -38.67 | -141.41 | -99.64 | -66.66 |
Depreciation/Amortization & Depletion | 0.63 | 0.25 | 0.21 | -0.17 | -0.12 |
Net Change from Assets/Liabilities | -8.24 | -5.58 | 2.17 | -7.77 | -9.96 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 13.80 | 6.53 | 21.03 | 16.57 | 10.91 |
Net Cash From Operating Activities | -68.30 | -37.46 | -118.00 | -91.01 | -65.84 |
Property & Equipment | -0.04 | 0.00 | -0.11 | -0.08 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 29.89 | 20.89 | -28.50 | -35.00 | -47.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 29.85 | 20.89 | -28.61 | -35.07 | -46.99 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.26 | 0.26 | 26.63 | 26.70 | 0.48 |
Issuance (Repayment) of Debt | -17.70 | 0.00 | 0.00 | -0.74 | -0.42 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | -17.44 | 0.26 | 26.63 | 25.97 | 0.06 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -55.90 | -16.32 | -119.98 | -100.11 | -112.76 |
Cash at Beginning of Period | 120.57 | 120.57 | 240.55 | 240.55 | 240.55 |
Cash at End of Period | 64.68 | 104.25 | 120.57 | 140.44 | 127.79 |
Diluted Net EPS | -0.63 | -0.68 | -0.74 | -0.61 | -0.61 |